🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2025-522407-23-00
Ongoing Phase II

A Phase IIb, Randomised, Multicentre, Double-Blind Study to Evaluate the Effect of Baxdrostat in Combination with Dapagliflozin Compared with Baxdrostat on Albuminuria in Participants with Chronic Kidney Disease and High Blood Pressure

2025-522407-23-00 · tracked via the Priya Life Science EU tracker
Sponsor
AstraZeneca AB
Sponsor type
Pharmaceutical company
Therapeutic area
Cardiovascular Diseases
Decision date
16/02/2026
Enrollment target
18
Sites
Spain, Bulgaria

Condition studied

Chronic kidney disease (CKD) and hypertension.

Investigational medicinal product(s)

BaxdrostatForxiga 10 mg film-coated tabletsDapagliflozin Placebo

Eligibility

Age group
18-64 years, 65+ years
Sex
Female, Male

Primary endpoint

Change from baseline in UACR at Week 12

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-522407-23-00 on CTIS ↗ ← All trials in the EU